A meta-analysis of 14 trials involving four nonergot dopamine agonists -- first-line treatments for restless legs syndrome -- found that the drug ropinerole appeared to cause the "most profound side effects," leading patients to stop therapy. The American College of Neurology will release guidelines on the use of NEDA medicines by the end of the year, an expert said.

Full Story:

Related Summaries